ABBVIE INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 161.2 USD | +3.15% |
|
+2.66% | +4.05% |
| Sales 2024 * | 5.52TCr 4,60300Cr | Sales 2025 * | 5.81TCr 4,84400Cr | Capitalization | 28TCr 23,75000Cr |
|---|---|---|---|---|---|
| Net income 2024 * | 773.9Cr 65TCr | Net income 2025 * | 1.06TCr 88TCr | EV / Sales 2024 * | 6.21 x |
| Net Debt 2024 * | 5.79TCr 4,83100Cr | Net Debt 2025 * | 4.92TCr 4,10500Cr | EV / Sales 2025 * | 5.75 x |
| P/E ratio 2024 * |
31.3
x | P/E ratio 2025 * |
24.1
x | Employees | 50,000 |
| Yield 2024 * |
3.86% | Yield 2025 * |
4.03% | Free-Float | 96.38% |
More Fundamentals
* Assessed data
More news
Latest transcript on AbbVie Inc.
More recommendations
More press releases
More news
| 1 day | +3.15% | ||
| 1 week | +2.66% | ||
| 1 month | -0.86% | ||
| 3 months | -8.41% | ||
| 6 months | +13.24% | ||
| Current year | +4.05% |
1 week
153.58
161.64
1 month
153.58166.49
Current year
153.58182.89
1 year
130.96182.89
3 years
105.56182.89
5 years
62.55182.89
10 years
45.45182.89
| Managers | Title | Age | Since |
|---|---|---|---|
Richard Gonzalez
CEO | Chief Executive Officer | 70 | 01/13/01 |
Scott Reents
DFI | Director of Finance/CFO | 57 | 01/13/01 |
Robert Michael
PSD | President | 53 | 01/12/01 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Roxanne Austin
BRD | Director/Board Member | 63 | 01/13/01 |
Edward Rapp
BRD | Director/Board Member | 66 | 01/13/01 |
| Director/Board Member | 70 | 01/13/01 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 7.12% | 6 M€ | -.--% | - | |
| 6.85% | 17 M€ | +6.09% | - | |
| 6.26% | 13 M€ | -.--% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 31/24/31 | 161.2 | +3.15% | 15,664,434 |
| 30/24/30 | 156.3 | +0.98% | 4,311,479 |
| 29/24/29 | 154.8 | -0.35% | 4,254,540 |
| 28/24/28 | 155.3 | -1.10% | 5,533,467 |
| 24/24/24 | 157.1 | -0.76% | 3,691,730 |
Delayed Quote Nyse, May 01, 2024 at 01:35 am IST
More quotes
AbbVie Inc. specializes in therapeutic drug research and development. Its products are intended for treating rheumatoid arthritis, psoriasis, Crohn's disease, thyroid disease, Parkinson's disease, HIV, complications of mucoviscidosis, low testosterone levels, and complications associated with chronic renal disease.
Net sales are distributed geographically as follows: the United States (77.1%), Germany (2.3%), Canada (2%), Japan (1.9%), China (1.7%), France (1.4%), Spain ( 0.9%), Italy (0.9%), Australia (0.9%), Brazil (0.8%), United Kingdom (0.8%) and others (9.3%).
Sector
Pharmaceuticals
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
28
Last Close Price
161.2
USD
Average target price
182.1
USD
Spread / Average Target
+12.95%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +4.05% | 28TCr | |
| +40.73% | 74TCr | |
| +32.83% | 60TCr | |
| -6.30% | 35TCr | |
| +15.15% | 32TCr | |
| +15.00% | 24TCr | |
| +9.78% | 21TCr | |
| -5.52% | 21TCr | |
| +6.17% | 16TCr | |
| -0.45% | 16TCr |
- Stock Market
- Equities
- ABBV Stock
